Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

View Full Paper
Ask AI
Bookmark
Share

Authors

DLDasom LeeKKKendall KozyCLClaire Lohman

Discussion

Loading...

Member takes

Overview

Phase 1b trial shows Axi-Cel-2 improves progression-free survival in high-risk lymphoma, indicating enhanced CAR T-cell activity.

Key Points

  • Evaluate the safety and efficacy of double-dose axicabtagene ciloleucel (Axi-Cel-2) for high-risk relapsed or refractory large B-cell lymphoma.
  • Phase 1b study including adults with high-risk relapsed or refractory large B-cell lymphoma
  • Participants received standard-of-care axi-cel followed by Axi-Cel-2
  • Safety monitored for dose-limiting toxicity and cytokine release syndrome
  • Overall response rate of 90.9% with complete response rate of 72.7%
  • No dose-limiting toxicity or serious adverse events within 28 days
  • Marked improvements in CAR T-cell effectiveness observed with significant molecular response indicators

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8d0https://doi.org/10.1182/blood-2025-671
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).2024 · 24 citations
  2. 2Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  3. 3Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK2026 · 2 citations
  4. 4Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial2025
  5. 5Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017 · 6,101 citations